Avalyn Pharma (AVLN) Stock Price, News & Analysis

Company Overview

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function. The company has also pursued additional inhaled therapies for fibrotic lung conditions, although the status and scope of its development programs may change as clinical research progresses.

Avalyn Pharma is headquartered in the United States and conducts its operations through the development of investigational medicines rather than through a commercial product portfolio. As a clinical-stage company, its programs remain subject to clinical testing and regulatory review before they can become broadly available to patients.

Key Stats

• Today's Range: $32.59 to $35.53
• 50-Day Range: $25.68 to $39.25
• 52-Week Range: $24.15 to $40.17
• Volume: 227,177 shs
• Average Volume: 186,818 shs
• Market Capitalization: $1.52 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Moderate Buy

Avalyn Pharma Stock Analysis - MarketRank™

Avalyn Pharma scored higher than 70% of companies evaluated by MarketBeat, and ranked 230th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Avalyn Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Avalyn Pharma has a consensus price target of $60.00, representing about 75.0% upside from its current price of $34.28.

Amount of Analyst Coverage

Avalyn Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Avalyn Pharma are expected to grow in the coming year, from ($3.81) to ($2.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avalyn Pharma is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avalyn Pharma is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.35% of the float of Avalyn Pharma has been sold short.

Short Interest Ratio / Days to Cover

Avalyn Pharma has a short interest ratio ("days to cover") of 11.34, which indicates bearish sentiment.

Change versus previous month

Short interest in Avalyn Pharma has recently decreased by 6.87%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avalyn Pharma does not currently pay a dividend.

Dividend Growth

Avalyn Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.54

News Sentiment

Avalyn Pharma has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Avalyn Pharma this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for AVLN on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Avalyn Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avalyn Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

Avalyn Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AVLN
• CIK: 1540171
• Web: www.avalynpharma.com
• Phone: (206) 707-0340
• Fax: N/A
• Employees: 55
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Avalyn Pharma: $60.00
• High Price Target: $80.00
• Low Price Target: $51.00
• Potential Upside/Downside: +75.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 33.12
• Quick Ratio: 33.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 44,330,000
• Free Float: N/A
• Market Cap: $1.52 billion
• Optionable: N/A
• Beta: N/A